{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:53:51Z","timestamp":1790790831775,"version":"4.1.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004914","name":"Ferring Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004914","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Follitropin delta is the first approved human recombinant follicle-stimulating hormone treatment administered through an algorithmic individualized dosing regimen based on body weight and anti-M\u00fcllerian hormone (AMH) levels. This study assesses the effectiveness and safety profile of follitropin delta in women na\u00efve to <jats:italic>in vitro<\/jats:italic> fertilization or intracytoplasmic sperm injection undergoing their first assisted reproductive technology cycle in a general clinical setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Study design<\/jats:title><jats:p>This prospective observational study was conducted from August 2022 to March 2024 across 14 fertility clinics in Denmark, Norway, Sweden, and Switzerland. Consenting women with infertility (\u226518 years old) receiving their first assisted reproductive technology cycle and first follitropin delta treatment were enrolled. Both fresh and frozen embryo transfers were evaluated. Follow-up continued until confirmed pregnancy outcome, early pregnancy loss, or study withdrawal. Data on follitropin delta usage, ovarian stimulation, embryo development, and safety were collected through electronic case-report forms. Patient-reported satisfaction with the follitropin delta pre-filled pen was assessed using patient questionnaires.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 201 women enrolled, 199 completed the study. Of these, 147 (73.9%) were aged &amp;lt;35 years (median 32 years). The primary reason for infertility was male factor (88\/199, 44.2%). Baseline characteristics included a mean body weight of 68.9 kg, and a mean AMH baseline concentration of 21.3 pmol\/L, with 130\/199 (65.3%) participants having AMH concentrations &amp;gt;15 pmol\/L. Overall, 169\/199 (84.9%) participants were prescribed follitropin delta according to the calculated algorithmic dose, with a mean starting dose of 10.2 \u00b5g and a mean duration of ovarian stimulation of 9.9 days. The gonadotropin-releasing hormone antagonist protocol was used in 171\/193 (88.6%) women. Almost half of the analysis population (93\/194, 47.9%) achieved the algorithm-targeted response of 8\u201314 oocytes retrieved, and &amp;gt;15 oocytes were obtained in 55\/194 (28.4%) women. Ongoing pregnancy rate assessed by ultrasonography 10\u201311 weeks after embryo transfer was 82\/155 (52.9%). Ovarian hyperstimulation syndrome (all mild cases) was reported in 8\/199 (4.0%) women. Almost all women (190\/193, 98.4%) expressed satisfaction with the injection pen.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The NORSOS study (NCT05499052) provides insights into the use of follitropin delta in routine clinical practice and complements previous evidence regarding its effectiveness and safety profile.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2025.1613680","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T04:12:45Z","timestamp":1757045565000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness and safety of follitropin delta in routine clinical practice in the Nordics and Switzerland (the NORSOS study): a prospective non-interventional study"],"prefix":"10.3389","volume":"16","author":[{"given":"Anja","family":"Pinborg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negjyp","family":"Sopa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erling","family":"Ekerhovd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavros I.","family":"Iliadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"June","family":"Kaspersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Gravotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Quaas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12958-024-01331-6","article-title":"The most appropriate indicators of successful ovarian stimulation","volume":"23","author":"Roque","year":"2025","journal-title":"Reprod Biol Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1016\/j.fertnstert.2014.08.013","article-title":"Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose-response trial in women undergoing in vitro fertilization\/intracytoplasmic sperm injection","volume":"102","author":"Arce","year":"2014","journal-title":"Fertil Steril"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S1701-2163(15)30417-5","article-title":"The prevention of ovarian hyperstimulation syndrome","volume":"36","author":"Corbett","year":"2014","journal-title":"J Obstet Gynaecol Can"},{"key":"B4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.fertnstert.2016.10.033","article-title":"Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial","volume":"107","author":"Nyboe Andersen","year":"2017","journal-title":"Fertil Steril"},{"key":"B5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13048-023-01202-5","article-title":"Comparison of anti-Mullerian hormone and antral follicle count in the prediction of ovarian response: a systematic review and meta-analysis","volume":"16","author":"Liu","year":"2023","journal-title":"J Ovarian Res"},{"key":"B6","unstructured":"REKOVELLE - Summary of Product Characteristics\n          \n          \n          \n          2016"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.636038","article-title":"New human follitropin preparations: How glycan structural differences may affect biochemical and biological function and clinical effect","volume":"12","author":"Dias","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.rbmo.2018.10.012","article-title":"Follitropin delta in repeated ovarian stimulation for IVF: a controlled, assessor-blind Phase 3 safety trial","volume":"38","author":"Bosch","year":"2019","journal-title":"Reprod BioMed Online"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2021.01.023","article-title":"Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF\/ICSI patients: a randomized controlled trial","volume":"42","author":"Ishihara","year":"2021","journal-title":"Reprod BioMed Online"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deab155","article-title":"A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF\/ICSI patients","volume":"36","author":"Qiao","year":"2021","journal-title":"Hum Reprod"},{"key":"B11","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12958-022-01016-y","article-title":"Comparative clinical outcome following individualized follitropin delta dosing in Chinese women undergoing ovarian stimulation for in vitro fertilization\/intracytoplasmic sperm injection","volume":"20","author":"Yang","year":"2022","journal-title":"Reprod Biol Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deae092","article-title":"BEYOND: a randomized controlled trial comparing efficacy and safety of individualized follitropin delta dosing in a GnRH agonist versus antagonist protocol during the first ovarian stimulation cycle","volume":"39","author":"Lobo","year":"2024","journal-title":"Hum Reprod"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/ajo.13090","article-title":"Is it possible to apply trial outcomes to a real-world population? A novel approach to External Validity Analysis","volume":"60","author":"Agresta","year":"2020","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e12573","DOI":"10.1002\/rmb2.12573","article-title":"Efficacy and safety of follitropin delta versus follitropin alpha\/beta in infertility treatment: A systematic review and meta-analysis","volume":"23","author":"Komiya","year":"2024","journal-title":"Reprod Med Biol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3390\/diagnostics13020177","article-title":"A narrative review discussing the efficiency of personalized dosing algorithm of follitropin delta for ovarian stimulation and the reproductive and clinical outcomes","volume":"13","author":"Doroftei","year":"2023","journal-title":"Diagnostics"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.992677","article-title":"Prospective multicenter non-interventional real-world study to assess the patterns of use, effectiveness and safety of follitropin delta in routine clinical practice (the PROFILE study)","volume":"13","author":"Blockeel","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2023.12.011","article-title":"Prospective multicenter observational real-world study to assess the use, efficacy and safety profile of follitropin delta during IVF\/ICSI procedures (DELTA Study)","volume":"293","author":"Porcu-Buisson","year":"2024","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmx017","article-title":"GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type","volume":"23","author":"Lambalk","year":"2017","journal-title":"Hum Reprod Update"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2021.12.013","article-title":"An eight centre, retrospective, clinical practice data analysis of algorithm-based treatment with follitropin delta","volume":"44","author":"Bachmann","year":"2022","journal-title":"Reprod BioMed Online"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deu053","article-title":"Association between response to ovarian stimulation and miscarriage following IVF: an analysis of 124\u2013351 IVF pregnancies","volume":"29","author":"Sunkara","year":"2014","journal-title":"Hum Reprod"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deaa008","article-title":"Low anti-Mullerian hormone level is not a risk factor for early pregnancy loss in IVF\/ICSI treatment","volume":"35","author":"Peuranpaa","year":"2020","journal-title":"Hum Reprod"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2023.11.013","article-title":"Electronic address: asrm@asrm.org. Prevention of moderate and severe ovarian hyperstimulation syndrome: a guideline","volume":"121","year":"2024","journal-title":"Fertil Steril"},{"key":"B23","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1093\/humrep\/dex334","article-title":"The number of oocytes retrieved during IVF: a balance between efficacy and safety","volume":"33","author":"Magnusson","year":"2018","journal-title":"Hum Reprod"},{"key":"B24","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/1477-7827-10-93","article-title":"A questionnaire-based survey to assess patient satisfaction, ease-of-learning, ease-of-use, injection site pain and overall patient satisfaction of the follitropin-alpha (Gonal-f) filled-by-mass (FbM) prefilled pen compared with other systems of gonadotrophin administration","volume":"10","author":"Utsunomiya","year":"2012","journal-title":"Reprod Biol Endocrinol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1613680\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T04:12:48Z","timestamp":1757045568000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1613680\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":24,"alternative-id":["10.3389\/fendo.2025.1613680"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1613680","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,5]]},"article-number":"1613680"}}